In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts 45 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative oncology DARPin® candidates presented; Recruitment hold in MP0250 NSCLC trial; Ongoing focus on multiple myeloma for MP0250 clinical development
Zurich-Schlieren, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending March 31, 2019. “Our team is focused on delivering on our strategic priorities by advancing clinical candidates MP0250 and...
Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting
Zurich-Schlieren, Switzerland, April 16, 2019. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority. At today’s...